Imaging
Sheila Angeles-Han, MD, MSc (she/her/hers)
Cincinnati Children's Hospital
Cincinnati, OH, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
Sunil Srivastava, MD
Cole Eye Institute/Cleveland Clinic
Cleveland, OH, United States
Disclosure(s): Allergan: Consultant (Ongoing); Bausch: Consultant (Ongoing); Eyepoint: Consultant (Ongoing), Grant/Research Support (Ongoing); Regeneron: Consultant (Ongoing), Grant/Research Support (Ongoing); Zeiss: Consultant (Ongoing)
Pediatric non-infectious ocular inflammation continues to be a significant source of morbidity in both developing and developed countries. Screening for ocular inflammation often requires a high index of suspicion and may be inadequate in certain populations and scenarios. Challenges to care include lack of standardized precision medicine tools to guide the initiation, duration, and withdrawal of biologic agents. Additional bedside imaging and biomarker modalities may allow clinical teams to enhance care and mitigate sequelae of unchecked ocular inflammation.
Speaker: Sunil Srivastava, MD – Cole Eye Institute/Cleveland Clinic
Speaker: Sheila Angeles-Han, MD, MSc (she/her/hers) – Cincinnati Children's Hospital